AVANIR Pharmaceuticals (FRA:AV2B) Net Margin % : -43.15% (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. AVANIR Pharmaceuticals's Net Income for the three months ended in Sep. 2014 was €-10.95 Mil. AVANIR Pharmaceuticals's Revenue for the three months ended in Sep. 2014 was €25.38 Mil. Therefore, AVANIR Pharmaceuticals's net margin for the quarter that ended in Sep. 2014 was -43.15%.

The historical rank and industry rank for AVANIR Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:AV2B' s Net Margin % Range Over the Past 10 Years
Min: -1389.34 Med: -251.42 Max: 1.84
Current: -43.85

FRA:AV2B's Net Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.53 vs FRA:AV2B: -43.85

AVANIR Pharmaceuticals Net Margin % Historical Data

The historical data trend for AVANIR Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Net Margin % Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Net Margin %

Get a 7-Day Free Trial

-922.05

-577.63

-144.75

-100.15

-43.85

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Net Margin %	Get a 7-Day Free Trial															-163.72	-40.93	-47.05	-44.35	-43.15

Competitive Comparison of AVANIR Pharmaceuticals's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVANIR Pharmaceuticals's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Net Margin % falls into.

AVANIR Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

AVANIR Pharmaceuticals's Net Margin for the fiscal year that ended in Sep. 2014 is calculated as

Net Margin	=	Net Income (A: Sep. 2014 )	/	Revenue (A: Sep. 2014 )
	=	-39.138	/	89.263
	=	-43.85 %

AVANIR Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2014 is calculated as

Net Margin	=	Net Income (Q: Sep. 2014 )	/	Revenue (Q: Sep. 2014 )
	=	-10.952	/	25.379
	=	-43.15 %

AVANIR Pharmaceuticals (FRA:AV2B) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

AVANIR Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Net Margin %

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines